Company Filing History:
2 out of 5 
2 out of 3 Years Active: 2018-2020
Title: Innovations of John James Mousseau
Introduction
John James Mousseau is a notable inventor based in Norwich, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as potentiators for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR). With a total of 4 patents to his name, Mousseau's work is pivotal in addressing various CFTR-associated disorders.
Latest Patents
Mousseau's latest patents focus on bicyclic heteroaryl derivatives as CFTR potentiators. These inventions relate to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives and their pharmaceutically acceptable salts. The compounds developed are designed to enhance the function of CFTR, which is crucial for the treatment of conditions such as cystic fibrosis, asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), and several other disorders. The inventions also include pharmaceutical compositions that may combine these compounds with additional therapeutic agents, providing a comprehensive approach to treatment.
Career Highlights
Throughout his career, Mousseau has worked with prominent organizations, including Cystic Fibrosis Foundation Therapeutics, Inc. and the Cystic Fibrosis Foundation. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Mousseau has collaborated with notable colleagues such as Joseph Walter Strohbach and David Christopher Limburg. These partnerships have further enriched his work and expanded the impact of his inventions.
Conclusion
John James Mousseau's innovative contributions to the field of pharmaceuticals, particularly in CFTR potentiation, highlight his importance as an inventor. His work continues to pave the way for advancements in the treatment of various health conditions.